ESMO Breast 2021 | Where does immuno-oncology fit in the treatment landscape of TNBC?

Rebecca Dent, MD, FRCP, National Cancer Centre Singapore, Singapore, discusses the role of immuno-oncology in the treatment of triple-negative breast cancer (TNBC), in particular talking on the use of immune checkpoint inhibitors and the presence of biomarkers such as tumor infiltrating lymphocytes (TILs) and PD-L1. Prof. Dent outlines data from clinical trials including the IMpassion130 trial (NCT02425891) and the IMpassion131 trial (NCT03125902), commenting on the approval of atezolizumab plus nab-paclitaxel. Prof. Dent also talks on the KEYNOTE-522 (NCT03036488) trial and the IMpassion030 trial (NCT03498716). This interview took place at the virtual European Society for Medical Oncology (ESMO) Breast Cancer Congress 2021.